Everything below concerns peptide drug. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
=== Non-invasive imaging === A variety of Sendai virus constructs carrying reporter genes were developed for non-invasive imaging of the virus infection in animals. They allow to study dynamics of SeV spread and clearance. Some of these constructs were designed to deliver luciferase genes, some to deliver green fluorescent protein (GFP), others to deliver red fluorescent protein (RFP).
== Description == The sucrose lysis test uses an isotonic sucrose solution to lower the ionic strength of serum, which triggers the activation of the classic complement pathway, leading to the lysis of cells that are sensitive to complement. In the sucrose lysis test, patient RBCs are washed and resuspended in a buffered sucrose solution. The solution is then incubated at a set temperature for a specified period, during which complement-mediated lysis occurs. After incubation, the solution is centrifuged, and the amount of hemoglobin released is measured spectrophotometrically. The degree of lysis is compared to that of control samples. Although more sensitive than the Ham test, it is not as specific since some RBCs hemolyze to a minor degree in autoimmune hemolytic anemias, leukemia, and aplastic anemia. Although affordable and straightforward to perform, the test is more labor-intensive because PNH RBCs have a short half-life in circulation.
These early structural studies were not followed up until recent years with the renewed interest in bottromycin. The structure was confirmed in the 1980s and 1990s to be a cyclic iminopeptide based on NMR studies, with a linear side chain connected to the macrocycle via an amidine linkage. Its absolute stereochemistry, however, was not characterized until 2009. Stereochemistry at carbon 18 and 25 was proposed by comparing predicted conformers obtained using molecular dynamics to experimental constraints obtained through NMR experiments. Stereochemistry at carbon 43 was confirmed by comparing 1H NMR of authentic hydrolysis product to a chemically synthesized sample of the same fragment. Finally, optical rotation, 1H NMR, and HRMS experiments of chemically synthesized bottromycin matched that of biologically produced bottromycin. The three-dimensional solution structure of bottromycin A2 was solved by NMR in 2012. The overall structure was obtained with good resolution (RMSD 0.74±0.59 Å), with a RMSD of 0.09±0.06 Å for the macrocycle. In this study, it was proposed that the methylated proline residue contributed to the restricted conformation of the macrocycle. The methylated proline and β-OMe alanine residues were found to be on the same face of bottroymycin A2 and it was suggested that this characteristic contributed to binding of bottromycin to the ribosomal A site.
== Legal status == In Hong Kong, etorphine is regulated under Schedule 1 of Chapter 134 of the Dangerous Drugs Ordinance. It can be used legally only by health professionals and for university research purposes. The substance can be given by pharmacists under a prescription. Anyone who supplies the substance without prescription can be fined HKD$10,000. The penalty for trafficking or manufacturing the substance is a HKD$5,000,000 fine and life imprisonment. Possession for consumption without licence from the Department of Health is illegal, with a HKD$1,000,000 fine and/or 7 years of jail time. In the Netherlands etorphine is a Schedule I drug of the Opium Law. It is used only for veterinary purposes in zoos to immobilise large animals. In the United States etorphine is listed as a Schedule I (i.e. as not having any legal use) drug with an ACSCN of 9056, although its hydrochloride salt is classified as Schedule II (i.e. as having a legal use, such as tranquilization of large animals) with an ACSCN of 9059. In the United Kingdom, under the Misuse of Drugs Act 1971, etorphine is controlled as a Class A substance. In Italy etorphine is illegal, as are the parent compounds Dihydroetorphine and Acetorphine. (Data from 2022)
Slavery among the Indigenous groups had a different meaning than it had for Europeans, since it originated from a diverse socioeconomic organization, in which asymmetries were translated into kinship relations.
Sources: en.wikipedia.org
Biological devolution or de-evolution is a misnomer, not only because it implies that organisms can only evolve backward or forward, but also because it implies that evolution may cause organisms to evolve in the "wrong" direction. The phrase "survival of the fittest" refers to biological fitness, not physical fitness. Biological fitness is the quantitative measure of individual reproductive success, e.g. the tendency of lineages containing individuals that produce more offspring in a particular environment to persist and thrive in that environment. Further, while the related concepts of "survival of the fittest" and "natural selection" are often used interchangeably, they are not the same: natural selection is not the only form of selection that determines biological fitness (see sexual selection, fecundity selection, viability selection, and artificial selection). Evolution does not "plan" to improve an organism's fitness to survive. This misconception is encouraged as it is common shorthand for biologists to speak of a purpose as a concise form of expression (sometimes called the "metaphor of purpose"); it is less cumbersome to say "Dinosaurs may have evolved feathers for courtship" than "Feathers may have been selected for when they arose as they gave dinosaurs a selective advantage during courtship over their non-feathered rivals". However, this can result in many students explaining evolution as an intentional and purposeful process. Mutations are not all equally likely, nor do they occur at the same frequency everywhere in the genome.
== Interactions == Co-administration with erythromycin, ketoconazole, azithromycin, fluoxetine, or cimetidine resulted in elevated blood plasma concentrations of desloratadine and its metabolite 3-hydroxydesloratadine in studies. However, no clinically relevant changes were observed.
=== Marine === Owing to their location along the Pacific shelf edge and the confluence of Okhotsk Sea gyre and the southward Oyashio Current, the Kuril islands are surrounded by waters that are among the most productive in the North Pacific, supporting a wide range and high abundance of marine life. Invertebrates: Extensive kelp beds surrounding almost every island provide crucial habitat for sea urchins, various mollusks and countless other invertebrates and their associated predators. Many species of squid provide a principal component of the diet of many of the smaller marine mammals and birds along the chain. Fish: Further offshore, walleye pollock, Pacific cod, several species of flatfish are of the greatest commercial importance. During the 1980s, migratory Japanese sardine was one of the most abundant fish in the summer. Pinniped: The main pinnipeds were a significant object of harvest for the indigenous populations of the Kuril islands, both for food and materials such as skin and bone. The long-term fluctuations in the range and distribution of human settlements along the Kuril island presumably tracked the pinniped ranges. In historical times, fur seals were heavily exploited for their fur in the 19th and early 20th centuries and several of the largest reproductive rookeries, as on Raykoke island, were extirpated. In contrast, commercial harvest of the true seals and Steller sea lions has been relatively insignificant on the Kuril islands proper.
The beta sheet (β-sheet, also β-pleated sheet) is a common motif of the regular protein secondary structure. Beta sheets consist of beta strands (β-strands) connected laterally by at least two or three backbone hydrogen bonds, forming a generally twisted, pleated sheet. A β-strand is a stretch of polypeptide chain typically 3 to 10 amino acids long with backbone in an extended conformation. The supramolecular association of β-sheets has been implicated in the formation of the fibrils and protein aggregates observed in amyloidosis, Alzheimer's disease and other proteinopathies.
Gary J. Patti is an American biochemist known for his research in metabolism and for using mass spectrometry to characterize biological processes. He is the Michael and Tana Powell Professor at Washington University in St. Louis. He is co-founder and Chief Scientific Officer of Panome Bio and an Associate Editor for Clinical & Translational Metabolism. Biemann Medal, 2024 ACS Midwest Award, 2023 Academy of Science Innovation Award, 2016 Edward Mallinckrodt Jr. Scholar Award, 2016 Pew Biomedical Scholars Award, 2015 Alfred P. Sloan Award, 2014 Camille Dreyfus Teacher-Scholar Award, 2014 Gary Patti publications indexed by Google Scholar
Sources: en.wikipedia.org
== Production == Small amounts of fission products are naturally formed as the result of either spontaneous fission of natural uranium, which occurs at a low rate, or as a result of neutrons from radioactive decay or reactions with cosmic ray particles. The microscopic tracks left by these fission products in some natural minerals (mainly apatite and zircon) are used in fission track dating to provide the cooling (crystallization) ages of natural rocks. The technique has an effective dating range of 0.1 Ma to >1.0 Ga depending on the mineral used and the concentration of uranium in that mineral. About 1.5 billion years ago in a uranium ore body in Africa, a natural nuclear fission reactor operated for a few hundred thousand years and produced approximately 5 tonnes of fission products. These fission products were important in providing proof that the natural reactor had occurred. Fission products are produced in nuclear weapon explosions, with the amount depending on the type of weapon. The largest source of fission products is from nuclear reactors. In current nuclear power reactors, about 3% of the uranium in the fuel is converted into fission products as a by-product of energy generation. Most of these fission products remain in the fuel unless there is fuel element failure or a nuclear accident, or the fuel is reprocessed.
=== Mechanism of action === Insulin degludec is an ultra-long acting insulin that, unlike insulin glargine, is active at a physiologic pH. The addition of hexadecanedioic acid via an amide linkage to lysine at the B29 position allows for the formation of multi-hexamers in subcutaneous tissues. This allows for the formation of a subcutaneous depot that results in slow insulin release into the systemic circulation.
Its main geographical units are: the Coastal Plain along the Gulf of Guinea, the Ashanti uplands in the centre, the Volta Basin in the east, which is dominated by Lake Volta, and the Northern Plains stretching to Burkina Faso. The highest point is Mount Afadja (885 m) in the Akwapim-Togo Range. The northernmost settlement in Ghana is Pulmakong near the Burkina Faso border, while the southernmost point is Cape Three Points.
Blast cell Blast cells are very immature cells that are normally found in the bone marrow, where they develop into mature cells (hematopoiesis) before being released into the blood. They can be identified by their large overall size, deep blue cytoplasm, and large nucleus with fine chromatin and prominent nucleoli. When seen on the blood smear, blast cells are an abnormal finding and may be indicative of acute leukaemia or other serious blood disorders. Rarely, they may be seen in severe cases of left shift. The presence of Auer rods inside blast cells indicates that they are of myeloid origin, which has important implications for leukaemia treatment. Other morphologic features can provide information about the lineage of blast cells: for example, myeloblasts tend to be large with distinct nucleoli, while lymphoblasts can be smaller with a denser chromatin pattern. However, these features are not diagnostic, and flow cytometry or special staining is generally used to confirm the lineage.
=== Substrate presentation === Substrate presentation is a process where the enzyme is sequestered away from its substrate. Enzymes can be sequestered to the plasma membrane away from a substrate in the nucleus or cytosol. Or within the membrane, an enzyme can be sequestered into lipid rafts away from its substrate in the disordered region. When the enzyme is released it mixes with its substrate. Alternatively, the enzyme can be sequestered near its substrate to activate the enzyme. For example, the enzyme can be soluble and upon activation bind to a lipid in the plasma membrane and then act upon molecules in the plasma membrane.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.